Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T17:47:23.350Z.
Calculation as of: 2026-10-06T17:47:23.350Z.
Quote observation: 2026-10-06T17:45:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
EARNINGS YIELD
N/A
MapLight Therapeutics, Inc.
Market Cap
$394.23M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$384.81M
Earnings Yield
N/A
TTM Avg
1.96%
3Y Avg
1.22%
5Y Avg
1.02%
Market Cap
$408.75M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$405.74M
Earnings Yield
N/A
TTM Avg
8.82%
3Y Avg
5.78%
5Y Avg
5.78%
Market Cap
$377.39M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $394.23M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | N/A | 7.77% | 7.77% | 5.78% |
| Orthofix Medical Inc. (OFIX)vs › | $384.81M | N/A | 1.96% | 1.22% | 1.02% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.75M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $404.65M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $406.41M | N/A | 5.34% | 5.37% | 5.37% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | N/A | 8.82% | 5.78% | 5.78% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.39M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $408.28M | N/A | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $410.17M | N/A | 3.29% | 3.29% | 3.29% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
